MX362215B - Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. - Google Patents

Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.

Info

Publication number
MX362215B
MX362215B MX2015014234A MX2015014234A MX362215B MX 362215 B MX362215 B MX 362215B MX 2015014234 A MX2015014234 A MX 2015014234A MX 2015014234 A MX2015014234 A MX 2015014234A MX 362215 B MX362215 B MX 362215B
Authority
MX
Mexico
Prior art keywords
wee
inhibitors
aminopyrido
pyrimidin
derivatives
Prior art date
Application number
MX2015014234A
Other languages
English (en)
Other versions
MX2015014234A (es
Inventor
Burkamp Frank
Roderick O´Dowd Colin
Samuel Shane Rountree James
John Wilkinson Andrew
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of MX2015014234A publication Critical patent/MX2015014234A/es
Publication of MX362215B publication Critical patent/MX362215B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a los compuestos de la fórmula (I) (ver Fórmula) que son útiles como inhibidores de la actividad de Wee-1 cinasa. La presente invención también se refiere a las composiciones farmacéuticas que contienen estos compuestos, y a los métodos para utilizar estos compuestos en el tratamiento de cáncer, y los métodos para tratar cáncer.
MX2015014234A 2013-04-11 2014-04-11 Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. MX362215B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1306610.5A GB201306610D0 (en) 2013-04-11 2013-04-11 Pharmaceutical compounds
PCT/GB2014/051136 WO2014167347A1 (en) 2013-04-11 2014-04-11 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Publications (2)

Publication Number Publication Date
MX2015014234A MX2015014234A (es) 2016-06-16
MX362215B true MX362215B (es) 2019-01-09

Family

ID=48537110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014234A MX362215B (es) 2013-04-11 2014-04-11 Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.

Country Status (15)

Country Link
US (1) US9714244B2 (es)
EP (1) EP2984090B1 (es)
JP (1) JP6412920B2 (es)
KR (1) KR102250668B1 (es)
CN (1) CN105209463B (es)
AU (1) AU2014252828B2 (es)
BR (1) BR112015026023A2 (es)
CA (1) CA2909365C (es)
GB (1) GB201306610D0 (es)
IL (1) IL242000B (es)
MX (1) MX362215B (es)
RU (1) RU2656342C2 (es)
SG (1) SG11201508405QA (es)
WO (1) WO2014167347A1 (es)
ZA (1) ZA201507874B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2817308B1 (en) * 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
WO2016204429A1 (ko) * 2015-06-18 2016-12-22 한국화학연구원 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물.
KR101845931B1 (ko) * 2015-06-18 2018-04-05 한국화학연구원 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
US10954253B2 (en) 2017-01-23 2021-03-23 Shijiazhuang Sagacity New Drug Development Co., Ltd. 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
AU2018243667A1 (en) 2017-03-31 2019-10-17 Seagen Inc. Combinations of Chk1- and Wee1 - inhibitors
US20200291018A1 (en) * 2017-07-13 2020-09-17 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
EP3694509A4 (en) 2017-10-09 2021-07-14 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2018361010B2 (en) 2017-11-01 2023-01-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as Wee1 inhibitor and applications thereof
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds
EP3875460A4 (en) 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF
KR102747104B1 (ko) * 2019-02-18 2024-12-27 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
JP2022528047A (ja) 2019-03-22 2022-06-08 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド Ｗｅｅ１阻害剤、その製造および用途
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
HUE068061T2 (hu) 2019-04-30 2024-12-28 Wuxi Biocity Biopharmaceutics Co Ltd WEE1 inhibitor vegyület kristályos formája és felhasználása
CA3180664A1 (en) 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
EP4332104A4 (en) 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
AU2022287033B2 (en) * 2021-06-04 2025-04-17 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
ES2432414T3 (es) * 2008-08-12 2013-12-03 Glaxosmithkline Llc Compuestos químicos
AU2009319051A1 (en) * 2008-11-28 2010-06-03 Novartis Ag Hsp90 inhibitors for therapeutic treatment
WO2010067886A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivative
WO2010067888A1 (en) * 2008-12-12 2010-06-17 Banyu Pharmaceutical Co.,Ltd. Dihydropyrimidopyrimidine derivatives
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
JP2014520855A (ja) * 2011-07-15 2014-08-25 アッヴィ・インコーポレイテッド 増殖性疾患の治療に有用な三環式キナーゼ阻害薬
US8796289B2 (en) * 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP2817308B1 (en) 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases

Also Published As

Publication number Publication date
GB201306610D0 (en) 2013-05-29
IL242000B (en) 2021-03-25
MX2015014234A (es) 2016-06-16
CN105209463B (zh) 2017-10-13
US20160060258A1 (en) 2016-03-03
AU2014252828A1 (en) 2015-11-05
ZA201507874B (en) 2017-09-27
RU2015148189A (ru) 2017-05-23
NZ713114A (en) 2021-01-29
SG11201508405QA (en) 2015-11-27
KR102250668B1 (ko) 2021-05-10
CN105209463A (zh) 2015-12-30
CA2909365A1 (en) 2014-10-16
BR112015026023A2 (pt) 2017-07-25
EP2984090A1 (en) 2016-02-17
CA2909365C (en) 2021-11-09
JP2016516763A (ja) 2016-06-09
EP2984090B1 (en) 2017-05-31
HK1219474A1 (en) 2017-04-07
WO2014167347A1 (en) 2014-10-16
JP6412920B2 (ja) 2018-10-24
US9714244B2 (en) 2017-07-25
AU2014252828B2 (en) 2018-07-05
KR20150143668A (ko) 2015-12-23
RU2656342C2 (ru) 2018-06-05

Similar Documents

Publication Publication Date Title
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX359418B (es) Pteridinas como inhibidores del receptor del factor de crecimiento de fribroblasto (fgfr).
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
PH12014502772A1 (en) Substituted tricyclic compounds as fgfr inhibitors
MY177344A (en) Compounds and their methods of use
IN2014KN02601A (es)
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX359656B (es) Derivados de oxoquinazolinil-butanamida.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX376090B (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas.
MX366140B (es) Derivados de urea de piperidinas.
MX2016008042A (es) Derivados de imidazopirazinona.
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
MX2015016760A (es) Derivados de ftalazina.
MY193381A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration